Arcellx

Arcellx is a clinical-stage biotechnology company pioneering innovative cell therapies for cancer and other incurable diseases. Our lead product candidate, CART-ddBCMA, is in Phase 1 trials for multiple myeloma and has received FDA Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations. We're also advancing our dosable and controllable CAR-T therapy, ARC-SparX, into clinical trials for multiple myeloma and acute myeloid leukemia. Arcellx is making significant strides in revolutionizing cell therapy, offering safer, more effective, and accessible treatments. We operate in a dynamic and rapidly evolving field, requiring a cutting-edge tech stack. Our team utilizes technologies such as Google Tag Manager, Google Font API, and leverages mobile-first design principles (iPhone/Mobile Compatible, Viewport Meta). We're committed to robust security (SSL by Default, SPF, DNSSEC, HSTS) and maintain a collaborative, innovative culture that values character, audacity, determination, collaboration, and originality. Our diverse and supportive environment empowers our employees to do their best work. Arcellx is a rapidly growing company with significant funding and a strong market position. We're a publicly traded company (NASDAQ: ACLX) with a workforce of 101-250 employees, dedicated to advancing humanity through safer and more effective cell therapies. We offer competitive salaries and benefits, including comprehensive health insurance, unlimited vacation, and generous parental leave. Join us in our mission to destroy cancer and advance humanity. Our commitment to excellence extends beyond our science. We cultivate a supportive and inclusive environment that fosters collaboration and innovation. Our teams are geographically distributed but highly connected, ensuring efficient communication and collaboration across projects.